AstraZeneca (AZN)
NASDAQ: AZN
· Real-Time Price · USD
72.82
1.95 (2.75%)
At close: May 30, 2025, 3:59 PM
73.34
0.72%
After-hours: May 30, 2025, 05:52 PM EDT
AstraZeneca Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|
| Enhertu Revenue | 1.02B | 58M | 1.1B | 888M | 1.28B | 1.32B | 735M |
| Enhertu Revenue Growth | +1662.07% | -94.71% | +23.42% | -30.52% | -3.26% | +79.73% | n/a |
| Bevespi Revenue | 58M | 398M | 17M | 1.18B | 1.58B | 584M | 1.08B |
| Bevespi Revenue Growth | -85.43% | +2241.18% | -98.56% | -25.36% | +170.72% | -45.88% | n/a |
| Breztri Revenue | 677M | 1.36B | 1.33B | n/a | 549M | 1.43B | 574M |
| Breztri Revenue Growth | -50.15% | +2.41% | n/a | n/a | -61.69% | +149.65% | n/a |
| Brilinta Revenue | 1.32B | 280M | 174M | n/a | 164M | 1.39B | 2.37B |
| Brilinta Revenue Growth | +372.86% | +60.92% | n/a | n/a | -88.21% | -41.18% | n/a |
| Bydureon Revenue | 163M | 9.19B | 948M | n/a | 1.54B | 297M | 1.07B |
| Bydureon Revenue Growth | -98.23% | +869.20% | n/a | n/a | +419.53% | -72.35% | n/a |
| CVRM Revenue | 10.59B | 2.06B | n/a | n/a | 704M | 1.03B | 941M |
| CVRM Revenue Growth | +414.58% | n/a | n/a | n/a | -31.52% | +9.25% | n/a |
| Calquence Revenue | 2.51B | 1.05B | n/a | n/a | 892M | 633M | 297M |
| Calquence Revenue Growth | +139.89% | n/a | n/a | n/a | +40.92% | +113.13% | n/a |
| Crestor Revenue | 1.11B | 189M | n/a | n/a | 1.47B | 647M | 1.95B |
| Crestor Revenue Growth | +485.71% | n/a | n/a | n/a | +127.05% | -66.85% | n/a |
| Daliresp/Daxas Revenue | 54M | 79M | n/a | n/a | 1.2B | 1.7B | 611M |
| Daliresp/Daxas Revenue Growth | -31.65% | n/a | n/a | n/a | -29.61% | +178.56% | n/a |
| Farxiga Revenue | 5.96B | 4.38B | n/a | n/a | 1.48B | 543M | 1.18B |
| Farxiga Revenue Growth | +36.11% | n/a | n/a | n/a | +173.11% | -53.83% | n/a |
| Fasenra Revenue | 1.55B | 1.4B | n/a | n/a | 527M | 1.29B | 2.8B |
| Fasenra Revenue Growth | +11.25% | n/a | n/a | n/a | -59.02% | -54.12% | n/a |
| Faslodex Revenue | 297M | 334M | n/a | n/a | 1.47B | 2.56B | 687M |
| Faslodex Revenue Growth | -11.08% | n/a | n/a | n/a | -42.76% | +272.78% | n/a |
| FluMist Revenue | 216M | 175M | n/a | n/a | 2.5B | 665M | 955M |
| FluMist Revenue Growth | +23.43% | n/a | n/a | n/a | +275.19% | -30.37% | n/a |
| Imfinzi Revenue | 4.24B | 2.78B | n/a | n/a | 3.19B | 1.86B | n/a |
| Imfinzi Revenue Growth | +52.19% | n/a | n/a | n/a | +71.45% | n/a | n/a |
| Kanuma Revenue | 171M | 160M | n/a | n/a | 813M | 752M | n/a |
| Kanuma Revenue Growth | +6.88% | n/a | n/a | n/a | +8.11% | n/a | n/a |
| Koselugo Revenue | 331M | 208M | n/a | n/a | 42M | 33M | n/a |
| Koselugo Revenue Growth | +59.13% | n/a | n/a | n/a | +27.27% | n/a | n/a |
| Lokelma Revenue | 412M | 289M | n/a | n/a | 14M | 62M | n/a |
| Lokelma Revenue Growth | +42.56% | n/a | n/a | n/a | -77.42% | n/a | n/a |
| Lynparza Revenue | 2.81B | 2.64B | n/a | n/a | 358M | n/a | n/a |
| Lynparza Revenue Growth | +6.56% | n/a | n/a | n/a | n/a | n/a | n/a |
| Nexium Revenue | 945M | 1.28B | n/a | n/a | 2M | n/a | n/a |
| Nexium Revenue Growth | -26.46% | n/a | n/a | n/a | n/a | n/a | n/a |
| Oncology, Others Revenue | 224M | 44M | n/a | n/a | n/a | n/a | n/a |
| Oncology, Others Revenue Growth | +409.09% | n/a | n/a | n/a | n/a | n/a | n/a |
| Onglyza Revenue | 227M | 257M | n/a | n/a | n/a | n/a | n/a |
| Onglyza Revenue Growth | -11.67% | n/a | n/a | n/a | n/a | n/a | n/a |
| Other, Others Revenue | 231M | 340M | n/a | n/a | n/a | n/a | n/a |
| Other, Others Revenue Growth | -32.06% | n/a | n/a | n/a | n/a | n/a | n/a |
| Pulmicort Revenue | 713M | 645M | n/a | n/a | n/a | n/a | n/a |
| Pulmicort Revenue Growth | +10.54% | n/a | n/a | n/a | n/a | n/a | n/a |
| Rare Disease Revenue | 7.76B | 7.05B | n/a | n/a | n/a | n/a | n/a |
| Rare Disease Revenue Growth | +10.08% | n/a | n/a | n/a | n/a | n/a | n/a |
| Roxadustat Revenue | 271M | 197M | n/a | n/a | n/a | n/a | n/a |
| Roxadustat Revenue Growth | +37.56% | n/a | n/a | n/a | n/a | n/a | n/a |
| Saphnelo Revenue | 280M | 862M | n/a | n/a | n/a | n/a | n/a |
| Saphnelo Revenue Growth | -67.52% | n/a | n/a | n/a | n/a | n/a | n/a |
| Seloken/Toprol-XL Revenue | 640M | 3.76B | n/a | n/a | n/a | n/a | n/a |
| Seloken/Toprol-XL Revenue Growth | -82.99% | n/a | n/a | n/a | n/a | n/a | n/a |
| Soliris Revenue | 3.15B | 958M | n/a | n/a | n/a | n/a | n/a |
| Soliris Revenue Growth | +228.29% | n/a | n/a | n/a | n/a | n/a | n/a |
| Strensiq Revenue | 1.15B | 2.54B | n/a | n/a | n/a | n/a | n/a |
| Strensiq Revenue Growth | -54.61% | n/a | n/a | n/a | n/a | n/a | n/a |
| Symbicort Revenue | 2.36B | 578M | n/a | n/a | n/a | n/a | n/a |
| Symbicort Revenue Growth | +308.65% | n/a | n/a | n/a | n/a | n/a | n/a |
| Synagis Revenue | 546M | 5.44B | n/a | n/a | n/a | n/a | n/a |
| Synagis Revenue Growth | -89.97% | n/a | n/a | n/a | n/a | n/a | n/a |
| Tagrisso Revenue | 5.8B | 14.63B | n/a | n/a | n/a | n/a | n/a |
| Tagrisso Revenue Growth | -60.36% | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Oncology Revenue | 17.14B | 1.63B | n/a | n/a | n/a | n/a | n/a |
| Total Oncology Revenue Growth | +955.08% | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Other medicines Revenue | 1.18B | 1.97B | n/a | n/a | n/a | n/a | n/a |
| Total Other medicines Revenue Growth | -40.15% | n/a | n/a | n/a | n/a | n/a | n/a |
| Ultomiris. Revenue | 2.96B | 1.8B | n/a | n/a | n/a | n/a | n/a |
| Ultomiris. Revenue Growth | +64.91% | n/a | n/a | n/a | n/a | n/a | n/a |
| Vaxzevria Revenue | 12M | 927M | n/a | n/a | n/a | n/a | n/a |
| Vaxzevria Revenue Growth | -98.71% | n/a | n/a | n/a | n/a | n/a | n/a |
| Zoladex Revenue | 952M | 150M | n/a | n/a | n/a | n/a | n/a |
| Zoladex Revenue Growth | +534.67% | n/a | n/a | n/a | n/a | n/a | n/a |
| Andexxa Revenue | 182M | 116M | n/a | n/a | n/a | n/a | n/a |
| Andexxa Revenue Growth | +56.90% | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 4.63B | 5.55B | 5.29B | 5.06B | 4.63B | 3.98B | 4.93B | 5.12B | 4.19B | 4.78B | 3.29B | 4.81B | 4.96B | 5.24B | 2.99B | 3.2B | 3.03B | 3.32B | 2.27B | 2.74B | 2.81B | 3.09B | 3.25B | 3.02B | 2.59B | 2.69B | 2.5B | 2.63B | 2.54B | 3.16B | 2.57B | 2.43B | 2.38B | 1.47B | 2.48B | 3.14B | 2.65B | 2.77B | 2.76B | 3.05B | 2.88B |
| Selling, General, and Administrative Revenue Growth | -16.68% | +5.01% | +4.49% | +9.31% | +16.24% | -19.19% | -3.67% | +22.04% | -12.23% | +45.42% | -31.70% | -3.12% | -5.27% | +75.52% | -6.72% | +5.71% | -8.77% | +46.21% | -17.12% | -2.39% | -9.25% | -4.86% | +7.47% | +16.67% | -3.75% | +7.89% | -5.28% | +3.82% | -19.76% | +22.93% | +5.88% | +2.23% | +61.81% | -40.74% | -21.13% | +18.69% | -4.30% | +0.33% | -9.57% | +6.05% | n/a |
| Research and Development Revenue | 3.16B | 4.68B | 3.12B | 3.01B | 2.78B | 3.07B | 2.58B | 2.67B | 2.61B | 2.63B | 2.36B | 2.55B | 2.13B | 2.58B | 2.15B | 1.83B | 1.71B | 1.72B | 1.45B | 1.39B | 1.39B | 2.07B | 1.33B | 1.36B | 1.27B | 2.01B | 1.28B | 1.36B | 1.28B | 1.55B | 1.4B | 1.35B | 1.45B | 1.54B | 1.4B | 1.47B | 1.48B | 1.75B | 1.43B | 1.47B | 1.36B |
| Research and Development Revenue Growth | -32.46% | +50.14% | +3.56% | +8.08% | -9.44% | +18.92% | -3.11% | +2.14% | -0.53% | +11.37% | -7.42% | +19.36% | -17.45% | +20.07% | +17.66% | +6.77% | -0.35% | +18.31% | +4.61% | +0.07% | -33.01% | +56.02% | -2.06% | +7.11% | -37.08% | +57.31% | -6.09% | +6.49% | -17.54% | +10.47% | +4.08% | -7.16% | -5.83% | +10.06% | -4.30% | -1.01% | -15.23% | +22.18% | -2.52% | +8.11% | n/a |
| Sales and Marketing Revenue | 135M | 143M | 145M | 132M | 135M | 17.83B | 4.93B | 5.12B | 4.19B | 4.78B | 3.29B | 4.81B | 4.96B | 5.24B | 2.99B | 3.2B | 3.03B | 3.32B | 2.27B | 2.74B | 2.81B | 3.09B | 3.25B | 3.02B | 2.59B | 2.69B | 2.5B | 2.63B | 2.54B | 3.16B | 2.57B | 2.43B | 2.38B | 1.47B | 2.48B | 3.14B | 2.65B | 2.77B | 2.76B | 3.05B | 2.88B |
| Sales and Marketing Revenue Growth | -5.59% | -1.38% | +9.85% | -2.22% | -99.24% | +261.70% | -3.67% | +22.04% | -12.23% | +45.42% | -31.70% | -3.12% | -5.27% | +75.52% | -6.72% | +5.71% | -8.77% | +46.21% | -17.12% | -2.39% | -9.25% | -4.86% | +7.47% | +16.67% | -3.75% | +7.89% | -5.28% | +3.82% | -19.76% | +22.93% | +5.88% | +2.23% | +61.81% | -40.74% | -21.13% | +18.69% | -4.30% | +0.33% | -9.57% | +6.05% | n/a |